Antibodies, Bispecific

Bristol Myers Squibb Commits Up to $11B+ in Major BioNTech Solid Tumor Bispecific Antibody Deal

5 days ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327, Immunotherapy for cancer, milestone payments, Myers, Partnership, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; solid tumors; PD-L1; VEGF-A; cancer immunotherapy; partnership; milestone payments

Bristol Myers Squibb Signs $11B Deal With BioNTech for Bispecific Cancer Antibody BNT327, Surpassing Recent Merck and Pfizer Moves

6 days ago talkbio0Tagged Antibodies, Bispecific, BioNTech, biotech partnerships, BNT327, immuno-oncology, Malignant Neoplasms, Myers, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; immuno-oncology; cancer; PD-L1; VEGF-A; solid tumors; biotech partnerships

J&J Presents First Survival Data for KLK2-Targeted Bispecific Pasritamig in Prostate Cancer at ASCO 2025

6 days ago talkbio0Tagged Antibodies, Bispecific, ASCO, Human Glandular Kallikrein 2, Immunotherapy, Johnson and Johnson, Malignant neoplasm of prostate, Metastatic castration-resistant prostate cancer, pasritamig, survival data

Johnson & Johnson; pasritamig; bispecific antibody; ASCO 2025; prostate cancer; KLK2; metastatic castration-resistant prostate cancer (mCRPC); survival data; immunotherapy

Regeneron Secures EU Approval for Bispecific Antibody Lynozyfic, Positioning for Competition Against J&J and Pfizer

1 month ago talkbio0Tagged Antibodies, Bispecific, Approved, EU, J&J, Lynozyfic, Multiple Myeloma, Neoplasms, Pfizer, Regeneron

Regeneron, Lynozyfic, Bispecific Antibody, Multiple Myeloma, EU Approval, J&J, Pfizer, Oncology

‘Deviated from the core’: Akeso CEO tries to reset expectations of bispecific’s survival readout amid market tumult

1 month ago talkbio0Tagged Antibodies, Bispecific, Ivonescimab, Keytruda, Keytruda head-to-head trial, Market, Non-Small Cell Lung Carcinoma, Overall Survival, PD-1xVEGF, Reaction, summit

Ivonescimab, PD-1xVEGF bispecific antibody, Overall survival (OS) readout, Keytruda head-to-head trial, HARMONi-2 trial, Non-small cell lung cancer (NSCLC), Market reaction, Summit Therapeutics